Palvella Therapeutics (PVLA) Expected to Release Earnings on Tuesday

Palvella Therapeutics (NASDAQ:PVLA) is anticipated to post its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of ($1.16) per share for the quarter. Parties can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, analysts expect Palvella Therapeutics to post $-5 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Palvella Therapeutics Stock Down 0.2%

Shares of PVLA stock opened at $142.60 on Thursday. The firm has a market capitalization of $2.04 billion, a price-to-earnings ratio of -34.20 and a beta of -0.20. The stock has a fifty day moving average of $129.01 and a 200 day moving average of $117.73. Palvella Therapeutics has a 52 week low of $34.57 and a 52 week high of $161.38.

Wall Street Analyst Weigh In

Several research analysts have commented on PVLA shares. HC Wainwright restated a “buy” rating and issued a $270.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Chardan Capital reaffirmed a “buy” rating and set a $240.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Stephens reiterated an “overweight” rating and set a $220.00 price target on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Wall Street Zen downgraded shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $199.53.

Insider Buying and Selling at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total transaction of $476,360.46. Following the completion of the transaction, the chief operating officer owned 2,154 shares of the company’s stock, valued at approximately $238,512.42. This trade represents a 66.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 17.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PVLA. Invesco Ltd. raised its stake in Palvella Therapeutics by 11.6% during the fourth quarter. Invesco Ltd. now owns 54,273 shares of the company’s stock valued at $5,681,000 after buying an additional 5,663 shares during the last quarter. XTX Topco Ltd bought a new stake in Palvella Therapeutics in the fourth quarter worth $429,000. Virtus Investment Advisers LLC purchased a new stake in shares of Palvella Therapeutics in the fourth quarter worth $282,000. Superstring Capital Management LP purchased a new stake in shares of Palvella Therapeutics in the fourth quarter worth $2,666,000. Finally, Suvretta Capital Management LLC increased its holdings in shares of Palvella Therapeutics by 8.5% during the fourth quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock valued at $93,408,000 after acquiring an additional 70,000 shares in the last quarter. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.